Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
03:07pm, Monday, 30'th Dec 2024
Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 11'th Dec 2024
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Tuesday, 05'th Nov 2024
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Friday, 01'st Nov 2024
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
03:24pm, Tuesday, 08'th Oct 2024
Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
04:01pm, Monday, 07'th Oct 2024
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
10:00am, Sunday, 22'nd Sep 2024
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass.
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
01:01pm, Thursday, 08'th Aug 2024
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Tuesday, 06'th Aug 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
09:51am, Friday, 10'th May 2024
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Thursday, 09'th May 2024
CAMBRIDGE, MA, May 09, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic muta
